Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Phone-Based navigation could boost breast cancer detection in kenya

NCT ID NCT07764796

Prevention Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study tests whether mobile health (m-Health) patient navigation—using phone apps for education, reminders, and motivation—can help more women in Kenyan primary care clinics get screened for breast cancer. The trial involves 800 women and aims to improve access to mammography and clinical breast exams, which are underused despite being available. By linking patients to screening and follow-up care, the approach could lead to earlier detection and better outcomes for breast cancer, a disease that is highly curable when caught early.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mobile health (m-Health) patient navigation strategies, including digital platforms and tools for education, reminders, navigation, and motivation
What this could lead to
If effective, this approach could increase breast cancer screening rates and early detection in Kenya, potentially saving lives by catching cancer when it is most treatable.
What could go wrong
This is an early-stage implementation study, so it may not show a clear benefit. Success depends on real-world factors like phone access, health system readiness, and patient engagement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * AIM 1: All members of BREAKTHROUGH's Stakeholder Advisory Board (SAB) breast cancer working group * AIM 1: Participants (patients and health providers) from primary health care clinics in Nairobi County * AIM 1: Will include women (patients) aged over 35 years and speak either Kiswahili or English * AIM 1: Include women who: * Have never undergone MMG screening * Previously undergone MMG screening * Experienced breast abnormalities and have been referred for or undergone diagnostic investigations * Are currently undergoing or have received breast cancer treatment * AIM 1: Health care providers and breast screening facility staff (i.e. primary care clinic nurses, MMG clinic staff and technicians) will also be recruited * AIM 2: Will engage with a diverse group of local and national interagency stakeholders, Nairobi County health leadership, and health providers across different levels of the health system * AIM 3: Women aged 35 years and older who are able to provide informed consent who are attending the outpatient clinics for primary health care * AIM 4: Members of SAB breast cancer group, health facilities leadership (all health facility levels) Exclusion Criteria: * AIM 1: Those who will be unwilling to consent and those who are unable to consent will be excluded from the study * AIM 2: Those who will be unwilling to consent and those who are unable to consent will be excluded from the study * AIM 3: Women undergoing breast cancer treatment and women aged 70 years and above will be excluded * AIM 4: Members of SAB breast cancer group, and health facilities leadership who will be unwilling and unable to consent will be excluded

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.